乳腺癌微环境中趋化因子CCL20作用的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.010

摘要/Abstract

摘要： 趋化因子是一类低分子量细胞因子,在调节肿瘤微环境中发挥重要作用。肿瘤微环境中的趋化因子不仅能够趋化白细胞,也能诱导附近的反应细胞影响肿瘤生长、侵袭、转移和血管生成。趋化因子与炎症和肿瘤疾病的发生发展密切相关,其中CC家族中的趋化因子CCL20在多种恶性肿瘤的侵袭和转移中发挥重要作用。近年发现,趋化因子CCL20在乳腺癌免疫抑制、血管生成及诱导上皮间质转化和肿瘤侵袭转移中起重要的调控作用。然而,CCL20在乳腺癌中的作用机制尚未明确。本文重点阐述趋化因子CC亚家族成员CCL20在乳腺癌微环境中的功能,探讨CCL20与乳腺癌微环境之间的关系,以期为乳腺癌靶向治疗提供新的思路。

关键词: 肿瘤微环境, 趋化因子, CCL20, 乳腺癌

Abstract: Chemokines are a class of low molecular weight cytokines,which play an important role in regulating the tumor microenvironment.Chemokines in the tumor microenvironment can not only trend chemotactic leukocytes,but also induce nearby respond cells to affect tumor growth,invasion,metastasis and angiogenesis.Chemokines are closely related to the occurrence and development of inflammation diseases and tumors.Among them,chemokine CCL20 in the CC family plays an important role in the invasion and metastasis of various malignant tumors.In recent years,it has been found that the chemokine CCL20 plays an important regulatory role in breast cancer immunosuppression,angiogenesis,induction of epithelial-mesenchymal transition,tumor invasion and metastasis.However,the mechanism of CCL20 action in breast cancer is not fully understood.This article focuses on the function of CCL20,a member of the chemokine CC subfamily,in the breast cancer microenvironment,and discusses the relationship between CCL20 and the breast cancer microenvironment,in order to provide new ideas for breast cancer targeted therapy.

Key words: Tumor microenvironment, Chemokine, CCL20, Breast cancer

中图分类号:

R737.9

刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.

LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment[J]. Journal of Practical Oncology, 2022, 36(3): 250-254.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.03.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I3/250

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Chen KL,Li L,Yang FX,et al.SIRT7 depletion inhibits cell proliferation,migration,and increases drug sensitivity by activating p38MAPK in breast cancer cells[J].J Cell Physiol,2018,233(9):6767-6778.
3 Silva P,Borges BC,Uehara IA,et al.Chemokines and the extracellular matrix:set of targets for tumor development and treatment[J].Cytokine,2021(42):155548.
4 Furue K,Ito T,Tsuji G,et al.The CCL20 and CCR6 axis in psoriasis[J].Scand J Immunol,2020,91(3):e12846.
5 袁思敏,杨勇,王雪莹,等.CCL20-CCR6轴与上皮-间质转化在乳腺癌中的研究进展[J].国际外科学杂志,2021,48(6):401-405.
6 唐妍,张梦梅,王菲,等.肿瘤微环境中的各组成成分在肿瘤发生、发展中的作用[J].中国医药导报,2018,15(6):39-43.
7 何嘉慧,王熙才,王佶,等.肿瘤微环境与乳腺癌细胞糖代谢重编程研究进展[J].肿瘤学杂志,2021,27(5):359-363.
8 封贺,王建莉,路小超,等.肿瘤相关巨噬细胞的研究进展[J].生命科学,2019,31(3):217-224.
9 杨云松,江一舟,胡欣,等.乳腺肿瘤微环境靶向治疗的研究进展[J].中国癌症杂志,2019,29(12):977-984.
10 Zhang H,Chen K,Tan Q,et al.Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5[J].Nat Commun,2021,12(1):1-12.
11 Aravind A,Palollathil A,Rex DAB,et al.A multi-cellular molecular signaling and functional network map of C-C motif chemokine ligand 18(CCL18):a chemokine with immunosuppressive and pro-tumor functions[J].J Cell Commun Signal,2022,16(2):293-300.
12 温敏,刘莹莹,徐金锋,等.乳腺癌肿瘤微环境相关治疗靶点的研究进展[J].广东医学,2019,40(7):908-912.
13 姜懿纳,陈乃宏.CCL2/MCP-1在其相关疾病的机制研究[J].中国药理学通报,2016,32(12):1634-1638.
14 Meitei HT,Jadhav N,Lal G.CCR6-CCL20 axis as a therapeutic target for autoimmune diseases[J].Autoimmun Rev,2021,20(7):102846.
15 Nelson RT,Boyd J,Gladue RP,et al.Genomic organization of the CC chemokine MIP-3α/CCL20/LARC/Exodus/SCYA20,showing gene structure,splice variants,and chromosome localization[J].Genomics,2001,73(1):28-37.
16 Li L,Zhou J,Xu Y,et al.C-C chemokine receptor type 6 modulates the biological function of osteoblastogenesis by altering the expression levels of Osterix and OPG/RANKL[J].BioSci Trends,2021,15(4):240-248.
17 Fennen M,Weinhage T,Kracke V,et al.A myostatin-CCL20-CCR6 axis regulates Th17 cell recruitment to inflamed joints in experimental arthritis[J].Sci Rep,2021,11(1):1-12.
18 张娟.CCL20/CCR6轴和AEG-1对宫颈癌增殖侵袭的影响及机制研究[D].武汉:武汉大学,2017.
19 庄同田,易秀莉,亢盼,等.病毒感染对角质形成细胞CCL20表达的影响及其机制 [J].现代生物医学进展,2020,20(10):1840-1845.
20 Yu WQ,Ji NF,Gu CJ,et al.Coexpression of helios in Foxp3+ regulatory T cells and its role in human disease[J].Dis Markers,2021,2021:5574472.
21 Zhao X,Li Y,Wang X,et al.Synergistic association of Foxp3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer:a retrospective cohort study[J].Med,2019,98(50):e18403.
22 Chen B,Zhang D,Zhou J,et al.High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma[J].Oncol Rep,2013,30(3):1380-1390.
23 Zhou L,Li H,Zhang XX,et al.Rapamycin treated tol-dendritic cells derived from BM-MSCs reversed graft rejection in a rat liver transplantation model by inducing CD8+ CD45RC-Treg[J].Mol Immunol,2021,137:11-19.
24 Pakravan N,Abbasi A,Hassan ZM.Immunotherapy using oxygenated water and tumor-derived exosomes potentiates antitumor immune response and attenuates malignancy tendency in mice model of breast cancer[J].Oxid Med Cell Longev,2021,2021(3):1-15.
25 Chow MT,Luster AD.Chemokines in cancer[J].Cancer Immunol Res,2014,2(12):1125-1131.
26 Georgakopoulos-Soares I,Chartoumpekis DV,Kyriazopoulou V,et al.EMT factors and metabolic pathways in cancer[J].Front Oncol,2020,10:499.
27 Tran DD,Corsa CA,Biswas H,et al.Temporal and spatial cooperation of snail1 and twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence[J].Mol cancer Res,2011,9(12):1644-1657.
28 Martins LM,Dourado CSME,Campos-Verdes LM,et al.Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma:a randomized,double-blind study[J].Oncotarget,2019,10(64):6879-6884.
29 Huang H.Matrix metalloproteinase-9(MMP-9)as a cancer biomarker and MMP-9 biosensors:recent advances[J].Sens,2018,18(10):3249.
30 Muscella A,Vetrugno C,Marsigliante S.CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture[J].Mol Carcinog,2017,56(11):2461-2473.
31 Marsigliante S,Vetrugno C,Muscella A.CCL20 induces migration and proliferation on breast epithelial cells[J].J Cellular Physiol,2013,228(9):1873-1883.
32 Marsigliante S,Vetrugno C,Muscella A.Paracrine CCL20 loop induces epithelial‐mesenchymal transition in breast epithelial cells[J].Mol Carcinog,2016,55(7):1175-1186.
33 Moustakas A,Heldin CH.Induction of epithelial-mesenchymal transition by transforming growth factor β[J].Semin Cancer Biol,2012,22(5/6):446-454.
34 Li M,Li P,Zhang M,et al.Brucine suppresses breast cancer metastasis via inhibiting epithelial mesenchymal transition and matrix metalloproteinases expressions[J].Chin J Integr Med,2018,24(1):40-46.
35 牛明,于歌.Gankyrin促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J].实用肿瘤学杂志,2020,34(6):518-523.
36 Chen W,Qin Y,Wang D,et al.CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer[J].PLoS Biol,2018,16(7):e2005869.
37 陈为龙.CCL20对三阴性乳腺癌化疗疗效的调控和分子机制研究[D].合肥:中国科学技术大学,2019.
38 Jayaraman S,Doucet M,Kominsky SL.CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells[J].Oncol Lett,2018,15(1):871-878.
39 钱晨,彭柳莹,冯小可,等.雷公藤红素通过抑制趋化因子CCl4减少破骨细胞形成[J].辽宁中医杂志,2015,42(2):415-417.
40 谢玮.毛蕊异黄酮通过HOTAIR干预ER阴性乳腺癌细胞生长作用的研究[D].桂林:桂林医学院,2021.
41 Lee SK,Park KK,Kim HJ,et al.Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis[J].Sci Rep,2017,7(1):9610.
42 Kim KY,Baek A,Park YS,et al.Adipocyte culture medium stimulates invasiveness of MDA-MB-231 cell via CCL20 production.[J].Oncol Rep,2009,22(6):1497-1504.

[1]	杨子涵, 许守平, 庞达. 乳腺癌发生腋窝外三角组织转移特点与影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(3): 226-232.
[2]	何伟丹, 李志高. FSIP1促进乳腺癌细胞迁移和侵袭并导致患者不良预后[J]. 实用肿瘤学杂志, 2022, 36(3): 233-238.
[3]	杨姝娅, 刘文慧, 骆耐香. UCA1在乳腺癌中的研究现状和应用展望[J]. 实用肿瘤学杂志, 2022, 36(3): 263-267.
[4]	刘婉莹, 庞达. 乳腺浸润性微乳头状癌转移机制的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 268-272.
[5]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[6]	孙元元, 张苧之, 曹孟儒. 乳腺癌肺转移机制及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(2): 173-177.
[7]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[8]	陈赫, 王秋程, 程文. 自动乳腺超声诊断系统在乳腺癌方面的应用进展[J]. 实用肿瘤学杂志, 2022, 36(2): 193-196.
[9]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[10]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[11]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[12]	罗波, 张曲, 郑红梅, 梁新军, 周小妹, 吴新红. SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J]. 实用肿瘤学杂志, 2021, 35(6): 523-528.
[13]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[14]	牟冠男, 马强. NK细胞极化在子宫内膜癌中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 534-537.
[15]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.